Bionomics Limited (NASDAQ:BNOX – Get Rating) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $21.00.
Several research firms have weighed in on BNOX. Evercore ISI downgraded Bionomics to an “outperform” rating in a research note on Monday, May 16th. Zacks Investment Research cut Bionomics from a “buy” rating to a “hold” rating in a report on Friday, May 13th.
An institutional investor recently bought a new position in Bionomics stock. Woodline Partners LP bought a new position in Bionomics Limited (NASDAQ:BNOX – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 161,943 shares of the company’s stock, valued at approximately $2,032,000. Woodline Partners LP owned 2.89% of Bionomics as of its most recent SEC filing. 7.86% of the stock is owned by hedge funds and other institutional investors.
Bionomics Company Profile (Get Rating)
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder.
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.